Whalesbook
Global Expansion Takes Center Stage
Strides Pharma Science is shifting focus to faster global growth, building on its recently strengthened financial footing. The company has successfully halved its debt, achieving a net debt to EBITDA ratio of 1.6x as of Q3FY26, a significant improvement from FY23 leverage. This financial deleveraging has freed up capital for reinvestment, with a dual focus on maintaining its strong position in the U.S. market, which accounts for about 52% of FY26 revenue, and expanding more deeply into fast-growing markets outside the U.S. Executive Director Aditya Kumar noted that the U.S. business is profitable and sustainable, holding market-leading positions in over half its portfolio. However, the company is increasingly relying on non-U.S. markets, including the UK, Europe, Australia, and parts of Africa, which are growing at a faster percentage rate due to prior investments. This expansion strategy was recently strengthened by the acquisition of select Sandoz branded generics assets in Africa, expected to generate mid-50s million dollars in revenue with a 14-15% CAGR. Management also indicated a future focus on differentiated delivery formats, specialty products, and a shift towards chronic therapies within the U.S. market, aiming for $400 million in U.S. revenue by 2028.
Stronger Balance Sheet Fuels Growth
The company's financial recovery is closely linked to its balance sheet improvements. With net debt at Rs 1,435.8 crore and operating cash flow at Rs 484 crore for the nine months ended December 31, 2025, Strides Pharma shows improved financial health. Revenue for 9MFY26 was Rs 3,535.2 crore, up 4.7% year-over-year, with a healthy EBITDA margin of 19.4%. The current market capitalization is around ₹83-85 billion. While Strides reports a trailing P/E ratio of approximately 16.35, some analyses suggest higher figures up to 46.42 in certain reports, though the company's valuation is generally considered attractive against sector averages. The stock's trading price as of March 25, 2026, was around ₹929.20, showing an intraday uptrend. The stock has seen positive short-term momentum, gaining for three consecutive days and showing a year-over-year return of about 39.90% as of mid-February 2026, outperforming the Sensex.
Market Position and Industry Trends
Strides Pharma operates within a dynamic Indian pharmaceutical sector expected to grow 7-9% in 2026, driven by strong domestic demand, stable exports, and a move towards complex generics and biosimilars. The sector's evolution emphasizes quality, innovation, and regulatory alignment. Strides' P/E ratio of around 16.35 is significantly lower than the sector average of 58.66, positioning it as a value play. Competitors like Ajanta Pharma trade at a P/E of 36.33, and Gland Pharma at 34.40, highlighting Strides' relatively attractive valuation. The company's strategy of focusing on differentiated delivery formats and specialty products aligns with broader industry trends favoring higher-margin segments. However, its revenue growth over the past five years has been moderate at 10.6%, contrasting with strong profit growth of 124% CAGR over the same period, suggesting margin expansion has been a key driver.
Concerns Remain Despite Improvements
Despite recent financial improvements, Strides Pharma faces remaining concerns. A key concern is the high level of promoter share pledging, reported at around 30.6% of holdings, which could pressure stock prices during market swings. Furthermore, while the company reports a net debt to EBITDA of 1.6x, some outside analyses report a higher Debt to EBITDA ratio of 6.58 times, questioning leverage sustainability. Historically, the company faced regulatory issues; in July 2019, the U.S. FDA issued a warning letter citing significant CGMP violations, including the "uncontrolled destruction" of manufacturing records and evidence of adulteration at its Puducherry plant. The FDA evaluated corrective actions by May 2023, signaling resolution, but past quality control and data integrity issues remain a reputational risk. Geopolitical issues, such as those affecting West Asian supply chains, present ongoing external challenges, though the industry is said to be better prepared post-COVID. Long-term fundamental strength is questioned, with average Return on Capital Employed (ROCE) over recent years at a modest 7.27%.
Company Strategy and Analyst Views
Analyst views on Strides Pharma Science have been mixed. While one source indicates a 100% 'Buy' rating from analysts, MarketsMOJO had downgraded the stock to 'Sell' on February 16, 2026, citing technical deterioration and long-term fundamental concerns, before upgrading it back to 'Hold' on March 5, 2026, driven by improved technicals and Q3 FY25-26 results. This mixed view acknowledges operational improvements alongside ongoing risks. The company's consensus target price is about ₹1,080. Strides Pharma's strategy is geared towards disciplined mergers and acquisitions, focusing on expanding into related areas and using its current capabilities rather than high-risk diversification. The company is also exploring opportunities in GLP-1 drugs but remains cautious about immediate capital deployment. The company aims to balance growth ambitions with sound financial management, focusing on sustainable profits and ongoing debt reduction.